Focused On-demand Library for Lactase/phlorizin hydrolase

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P09848

UPID:

LPH_HUMAN

Alternative names:

Lactase/glycosylceramidase

Alternative UPACC:

P09848; Q4ZG58

Background:

Lactase/phlorizin hydrolase, also known as Lactase/glycosylceramidase, plays a crucial role in the digestion of lactose, the primary sugar in mammalian milk. It hydrolyzes lactose into D-glucose and D-galactose, facilitating nutrient absorption in the intestinal brush border membrane. This enzyme exhibits broad specificity, targeting beta-glucopyranosides and beta-galactopyranosides with varying preferences for aglycone moieties.

Therapeutic significance:

Congenital lactase deficiency, a rare gastrointestinal disorder marked by severe diarrhea in infants, underscores the enzyme's critical function. This condition, alongside lactose intolerance, highlights the enzyme's potential in therapeutic strategies aimed at managing lactase activity levels and improving gastrointestinal health.